Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy

Antiviral Therapy

Volumn 3, Issue SUPPL. 4, 1998, Pages 39-43

  Clumeck, Nathan ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE; ZIDOVUDINE;

CEREBROSPINAL FLUID; CLINICAL TRIAL; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS REPLICATION;

CLINICAL TRIALS; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; RETROVIRIDAE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZIDOVUDINE;

EID: 0031775541     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. Journal of American Medical Association 1997; 277:1962-1969.
2. Gulick R, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Rickman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997; 337:734-739.
3. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cells of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-733.
4. Gao WY, Shirasaka T, Johns DG, Broder S & Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine and dideoxyinosine in resting and activated peripheral blood mononuclear cells. Journal of Clinical Investigation 1993; 91:2326-2333.
5. Sommadossi J-P. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′,3′-dideoxynucleoside analogues. Journal of Infectious Diseases 1995; 171:S88-S92.
6. Shafer RW, Kogal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA 3rd, Gupta P, Rasheed S & Coombs R. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Journal of Infections Diseases 1994; 169:722-729.
7. Foudraine NA, Hoetelmans RMW, Lange JMA, de Wolf F, van Benthem BHB, Maas JJ, Keet IPM & Portegies P. Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351:1547-1551.